On February 11, 2020, the District Court for the District of Delaware ruled in favor of Venable Fitzpatrick clients Novartis Pharmaceuticals Corporation and Novartis AG, denying a motion by Hikma Pharmaceuticals International Limited to enforce a settlement agreement related to generic versions of Novartis’s Afinitor® product. The District Court denied Hikma’s motion from the bench after briefing and oral argument.
Venable Fitzpatrick attorney Laura Fishwick drafted the Novartis responsive brief, and Christina Schwarz argued on behalf of Novartis at the oral hearing. Novartis was also represented by attorneys Nicholas Kallas, Jared Stringham, Christopher Loh, and Kostas Katsiris.